Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer
More than half of patients benefit from rechallenge PRLT. Our analysis suggests that rechallenge may prolong survival in selected patients, with an acceptable safety profile.
Authors
- Elisabeth von Guggenberg (ORCID: https://orcid.org/0000-0003-4944-4705)
- Clemens Decristoforo (ORCID: https://orcid.org/0000-0003-0566-4036)
- Gianpaolo di Santo
- Steffen Bayerschmidt (ORCID: https://orcid.org/0000-0003-2628-6935)
- Jasmin Bektić (ORCID: https://orcid.org/0000-0003-3946-0840)
- Anna Sviridenko
- Isabel Heidegger-Pircher
- Irene Johanna Virgolini (ORCID: https://orcid.org/0000-0001-7097-6170)
- Giulia Santo (ORCID: https://orcid.org/0000-0001-6565-0686)
- Fabian Scherbauer
- Peter Lehmann
- Lukas Wirth
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Magna Graecia University (IT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1007/s00259-024-06905-5
- Citations
- 9
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.77